Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review

Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajmal, Muhammad, Friedman, Jacob, Sipra, Qurat Ul Ain Riaz, Lassar, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810545/
https://www.ncbi.nlm.nih.gov/pubmed/33505518
http://dx.doi.org/10.1155/2021/8886210
_version_ 1783637323100979200
author Ajmal, Muhammad
Friedman, Jacob
Sipra, Qurat Ul Ain Riaz
Lassar, Tom
author_facet Ajmal, Muhammad
Friedman, Jacob
Sipra, Qurat Ul Ain Riaz
Lassar, Tom
author_sort Ajmal, Muhammad
collection PubMed
description Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
format Online
Article
Text
id pubmed-7810545
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-78105452021-01-26 Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review Ajmal, Muhammad Friedman, Jacob Sipra, Qurat Ul Ain Riaz Lassar, Tom Cardiovasc Ther Review Article Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses. Hindawi 2021-01-08 /pmc/articles/PMC7810545/ /pubmed/33505518 http://dx.doi.org/10.1155/2021/8886210 Text en Copyright © 2021 Muhammad Ajmal et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ajmal, Muhammad
Friedman, Jacob
Sipra, Qurat Ul Ain Riaz
Lassar, Tom
Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title_full Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title_fullStr Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title_full_unstemmed Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title_short Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
title_sort rivaroxaban: expanded role in cardiovascular disease management—a literature review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810545/
https://www.ncbi.nlm.nih.gov/pubmed/33505518
http://dx.doi.org/10.1155/2021/8886210
work_keys_str_mv AT ajmalmuhammad rivaroxabanexpandedroleincardiovasculardiseasemanagementaliteraturereview
AT friedmanjacob rivaroxabanexpandedroleincardiovasculardiseasemanagementaliteraturereview
AT sipraquratulainriaz rivaroxabanexpandedroleincardiovasculardiseasemanagementaliteraturereview
AT lassartom rivaroxabanexpandedroleincardiovasculardiseasemanagementaliteraturereview

Ejemplares similares